Download Full Text (868 KB)
Breast cancer has the highest incidence rate of all cancers globally in women, and those of African descent, especially West African females, face higher rates of triple-negative breast cancer (TNBC), a more aggressive form of breast cancer. Immunotherapy for breast cancer is a relatively new treatment option, and research is ongoing to identify the best combination treatments for increasing survival of those diagnosed with TNBC. Eganelisib (IPI-549: a PI3K-gamma inhibitor that works to shift M2 macrophages to M1 to augment T cell function) with other combinatory treatments has shown promising results in reducing tumor growth and increasing survival in mice. We have been conducting experiments to determine the most effective treatment regimen that will reduce growth of 4T1 mammary cancers, a murine TNBC model in syngeneic BalbC female mice. Combinations of eganelisib, cyclophosphamide, and anti-PD-1 or anti-PD-L1 have been tested to determine how immunotherapy and chemotherapy can induce a strong immune response, resulting in better responses to chemotherapy. Our current data indicates that a treatment regimen combining eganelisib, cyclophosphamide, and anti-PD-1 was most effective at suppressing tumor growth, compared to other treatments that only included one or two of these treatments. Mean tumor sizes of mice treated with a combination of eganelisib and other treatments were 187±70 mm3, 232±71 mm3, and 227±59 mm3 at the end of the experiments, compared to control data of 576±137 mm3, 414±31 mm3, and 591±200 mm3, respectively. These results could lead to further research on effective immunotherapy treatment combinations for TNBC.
Breast Cancer, Immunotherapy, Chemotherapy
Immunotherapy | Medicine and Health Sciences | Oncology | Women's Health
Current Academic Year
Dr. Harry Bear
Dr. Santiago Lima
© The Author(s)